Methods and compositions for treating motor neuron diseases

Combining nicotinamide riboside, pterostilbene, and ibudilast provides a promising treatment for ALS by targeting neuroinflammation and motor neuron degeneration, enhancing survival and function in mouse models.

JP7580380B2Active Publication Date: 2024-11-11UNIV DE VALENCIA +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021545301
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-28
Filing Date
2020-02-25
Publication Date
2024-11-11
Estimated Expiration
2040-02-25

AI Technical Summary

Technical Problem

Current treatments for motor neuron diseases like ALS have limited therapeutic benefits, with anti-inflammatory drugs showing mixed results, and there is a need for more effective strategies to address neuroinflammation and motor neuron degeneration.

Method used

Administering a combination of nicotinamide riboside, pterostilbene, and a phosphodiesterase (PDE) inhibitor like ibudilast, potentially enhanced by acetylcysteine, to target neuroinflammation and slow or reverse motor neuron degeneration.

Benefits of technology

The combination therapy significantly prolongs survival and improves motor function in mouse models of ALS, demonstrating a synergistic effect beyond individual treatments, with improved motor neuron-dependent functions and reduced neuroinflammation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580380000016
    Figure 0007580380000016
  • Figure 0007580380000017
    Figure 0007580380000017
  • Figure 0007580380000018
    Figure 0007580380000018
Patent Text Reader

Abstract

Provided herein are methods and compositions relating to treating a motor neuron disease, e.g., ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside, pterostilbene, and a phosphodiesterase (PDE) inhibitor, including a PDE4 inhibitor, e.g., ibudilast, and also comprising a thiol / cysteine ​​donor, e.g., acetylcysteine.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Provided herein are methods and compositions relating to treating a motor neuron disease, such as amyotrophic lateral sclerosis (ALS), in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside, pterostilbene, and a phosphodiesterase (PDE) inhibitor, including a PDE4 inhibitor, such as ibudilast. In further embodiments, a thiol / cysteine ​​donor, such as acetylcysteine, may also be added to the composition and / or administered to the subject to further enhance treatment. [Background technology]

[0002] Recent experiments evaluating motor function in amyotrophic lateral sclerosis (ALS) models showed positive effects of combined administration of nicotinamide riboside (NR) and pterostilbene PT (International Application PCT / US18 / 32932). Cheng Y, Di S, Fan C, Cai L, Gao C, Jiang P, Hu W, Ma Z, Jiang S, Dong Y, Li T, Wu G, Lv J, Yang Y. SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury. Apoptosis. 2016 August;21(8):905-16 showed that SIRT1 activation by pterostilbene attenuates skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury. Mendelsohn and Larrick (2014) studied middle-aged mice (with a first-stage OXPHOS defect) with nicotinamide adenine dinucleotide (NAD + showed that a one-week treatment with nicotinamide mononucleotide (NMN), a precursor of NAD, restored oxidative phosphorylation activity and other markers of mitochondrial function in skeletal muscle. +Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle (Frederick DW, Loro E, Liu L, Davila A Jr, Chellappa K, Silverman IM, Quinn WJ 3rd, Gosai SJ, Tichy ED, Davis JG, Mourkioti F, Gregory BD, Dellinger RW, Redpath P, Migaud ME, Nakamaru-Ogiso E, Rabinowitz JD, Khurana TS, Baur JA. Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metab. 2016 Aug 9;24(2):269-82) and + It has been shown that supplementation with NAD+ may be beneficial for patients with muscular dystrophies or other neuromuscular degenerative conditions characterized by the PARP / NNMT gene expression signature (Ryu D, Zhang H, Ropelle ER, Sorrentino V, Mazala DA, Mouchiroud L, Marshall PL, Campbell MD, Ali AS, Knowels GM, Bellemin S, Iyer SR, Wang X, Gariani K, Sauve AA, Canto C, Conley KE, Walter L, Lovering RM, Chin ER, Jasmin BJ, Marcinek DJ, Menzies KJ, Auwerx J. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci Transl Med. 2016 Oct 19;8(361):361ra139).

[0003] ALS-associated motor neuron degeneration is accompanied by axonal injury, glial activation, and the presence of inflammatory cells. Accumulating evidence suggests that neuroinflammation contributes to the neurodegeneration that is a hallmark of ALS (Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science 2016;353:777-783). Neuroinflammation is characterized by the presence of reactive astrocytes and microglia, moderate infiltration of peripheral immune cells, and elevated levels of inflammatory mediators, and is consistently observed in the motor cortex of the CNS in sporadic and familial ALS, constituting a hallmark of the disease (Liu J,Wang F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis:Cellular Mechanisms and Therapeutic Implications. Front Immunol.2017 Aug 21;8:1005).

[0004] Several clinical trials have tested the effect of various anti-inflammatory drugs (e.g. glucocorticoids or cyclooxygenase-2 inhibitors) in ALS (https: / / clinicaltrials.gov). However, although there has been much debate among experts and patients regarding the use of glucocorticoids as anti-ALS therapeutics (see, for example, various ALS-related forums https: / / www.als.net / forum / yaf_postst49865_dexamethasone.aspx), these trials have not found any therapeutic benefit that would justify their translation into clinical practice. However, some interesting findings suggest a potential positive effect. For example, the CNS-targeted anti-inflammatory agent 2B3-201 (liposomal methylprednisolone) has therapeutic potential and reduces brainstem pathology in the mouse model of ALS, SOD1G93A (Evans MC, Gaillard PJ, de Boer M, Appeldoorn C, Dorland R, Sibson NR, Turner MR, Anthony DC, Stolp HB. CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2014 Jun 13;2:66), or treatment with penicillin G and hydrocortisone has been shown to reduce ALS-associated symptoms: a case series of three patients (Tuk B, Jousma H, Gaillard PJ. Treatment with penicillin G and hydrocortisone reduces ALS-associated symptoms: a case series of three patients). Comparative efficacy of oral glucocorticoids shows that dexamethasone exhibits the highest efficacy (Chrousos G, Pavlaki AN, Magiakou MA (2011). Glucocorticoid Therapy and Adrenal Suppression. PMID 25905379).

[0005] Ibudilast (development code: AV-411 or MN-166) is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, maximally inhibiting PDE4 subtype, but also showing significant inhibition of other PDE subtypes. Ibudilast has bronchodilation, vasodilatory and neuroprotective effects, and is mainly used for the treatment of asthma and seizures. Ibudilast inhibits platelet aggregation and may also be useful for the treatment of multiple sclerosis. Interestingly, ibudilast, which shows anti-neuroinflammatory properties, has also been proposed for the treatment of ALS (Kalafer et al., 2014, U.S. Patent No. 9,314.452 B2). Summary of the Invention [Means for solving the problem]

[0006] According to certain aspects, methods and compositions related to treating a motor neuron disease (e.g., amyotrophic lateral sclerosis, or ALS) in a subject are provided herein by administering to the subject (e.g., orally administering to the subject) a compound of Formula I or Formula II (e.g., nicotinamide riboside), a compound of Formula III (e.g., pterostilbene), and a phosphodiesterase (PDE) inhibitor (e.g., ibudilast). In certain embodiments, the motor neuron disease includes ALS, hereditary spastic paraplegia (HSP), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP), pseudobulbar palsy, or spinal muscular atrophy. In further embodiments, acetylcysteine ​​can be added to the composition and / or administered to the subject to enhance treatment.

[0007] In certain aspects, the methods and compositions provided herein relate to slowing or reversing the progression of motor neuron degeneration in a subject by administering to the subject (e.g., orally administering to the subject) a compound of formula I or formula II (e.g., nicotinamide riboside), a compound of formula III (e.g., pterostilbene), and a phosphodiesterase (PDE) inhibitor, including PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 and PDE11 inhibitor, and in exemplary embodiments, a PDE4 inhibitor, such as ibudilast. In some embodiments, the subject has a motor neuron disease (e.g., ALS, HSP, PLS, PMA, PBP, pseudobulbar palsy or spinal muscular atrophy). In further embodiments, acetylcysteine ​​can be added to the composition and / or administered to the subject to enhance treatment. [Brief description of the drawings]

[0008] [Figure 1] Graph showing survival assay of SOD1 G93A mice treated with various compositions. WT, wild type. EH301 [nicotinamide riboside (NR) and pterostilbene (PT)] was administered orally: 185 mg nicotinamide riboside and / or 30 mg pterostilbene / Kg x day. Ibudilast (IBU) was administered orally: 12 mg / Kg x day. In this figure, it is shown that the combination of EH301 and ibudilast extends the survival time of SOD1 G93A AALS mice. [Figure 2A] (A) Graphs outlining individual study participant change from baseline in ALSFRS-R scores over 4 months. All participants enrolled in the study demonstrated a positive response in at least one of the endpoints. [Figure 2B] (B) Graphs outlining individual study participant's change from baseline in FVC (%) over 4 months. All participants enrolled in the study demonstrated a positive response in at least one of the endpoints. [Figure 2C](C) Graphs outlining individual study participant change from baseline over 4 months in MRC scale index. All participants enrolled in the study demonstrated a positive response in at least one of the evaluation items. [Figure 3A] 1 is a graph showing survival time of FUS R521C mice treated with nicotinamide riboside (NR) and pterostilbene (PT). [Figure 3B] 1 is a graph showing survival time of FUS R521C mice treated with nicotinamide riboside (NR), pterostilbene (PT) and ibudilast. [Figure 3C] 1 is a graph showing survival time of FUS R521C mice treated with nicotinamide riboside (NR), pterostilbene (PT), ibudilast and N-acetyl-cysteine ​​(NAC). [Figure 4] FIG. 1 shows the synthesis of NAC derivatives. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] [Definition] Before describing the present invention in detail, it is to be understood that this invention is not limited to particular modes of administration, patient populations, and the like, as such may vary, as will be apparent from the accompanying description and drawings.

[0010] It should be noted that, as used in this specification and the intended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a drug" includes a single drug as well as two or more of the same or different drugs, reference to "an optional excipient" refers to a single optional excipient as well as two or more of the same or different optional excipients, etc.

[0011] In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.

[0012] A "pharmaceutically acceptable excipient or carrier" refers to an excipient that may optionally be included in a composition of the present invention and that causes no significant adverse toxicological effects to a patient.

[0013] "Pharmaceutically acceptable salts" include, but are not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide and nitrate salts, or salts prepared from the corresponding inorganic acid forms of any of the above, such as hydrochloride salts, or salts prepared with organic acids, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate salts, as well as estolate, gluceptate and lactobionate salts.Similarly, salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium and ammonium (including substituted ammonium).

[0014] "Active molecules" or "active agents" as described herein include phosphodiesterase (PDE) inhibitors, including at least pterostilbene, nicotinamide riboside, and ibudilast.

[0015] "Substantially" or "essentially" means nearly the entirety or nearly the completeness of a given amount, e.g., 95% or greater.

[0016] "Optional" or "optionally" means that the situation described thereafter may or may not occur, and so the description includes examples where the situation occurs and examples where the situation does not occur.

[0017] The term "central nervous system" or "CNS" includes all cells and tissues of the vertebrate brain and spinal cord. Thus, the term includes, but is not limited to, neurons, glial cells, astrocytes, cerebrospinal fluid (CSF), interstitial spaces, etc.

[0018] "Glial cells" refers to various cells of the CNS also known as microglia, astrocytes, and oligodendrocytes.

[0019] The terms "subject", "individual" or "patient" are used interchangeably herein and refer to vertebrates, preferably mammals. Mammals include, but are not limited to, mice, rodents, monkeys, humans, livestock, sport animals and pets. The term "pharmacologically effective amount" or "therapeutically effective amount" of a composition or agent provided herein refers to a non-toxic but sufficient amount of the composition or agent to bring about the desired response, e.g., reduction or reversal of ALS. The exact amount required will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the condition being treated, the particular drug(s) used, the mode of administration, etc. The appropriate "effective" amount in any individual case can be determined by one of skill in the art using routine experimentation based on the information provided herein.

[0020] The term "about," particularly in reference to a given amount, is meant to encompass a deviation of plus or minus 5%.

[0021] "Treatment" or "treating" a progressive neurodegenerative disease includes arresting or reversing the progression of symptoms of a progressive neurodegenerative disease.

[0022] The methods of the present invention for the treatment of progressive neurodegenerative diseases are based on the administration of the following molecules: pterostilbene, nicotinamide riboside, and phosphodiesterase (PDE) inhibitors, such as ibudilast.

[0023] Phosphodiesterase (PDE) )」PDEs refer to a class of compounds that catalyze the hydrolysis of the 3'-carbon phosphate ester bond to generate the corresponding 5'-nucleotide monophosphate. They therefore regulate the cellular concentrations of cyclic nucleotides. Many hormone and neurotransmitter extracellular receptors utilize cyclic nucleotides as second messengers, and PDEs also regulate the cellular response to these extracellular signals. There are at least eight classes of PDEs: Ca2+ / calmodulin-dependent PDEs (PDE1), cGMP-stimulated PDEs (PDE2), cGMP-inhibited PDEs (PDE3), cAMP-specific PDEs (PDE4), cGMP-binding PDEs (PDE5), photoreceptor PDEs (PDE6), high-affinity cAMP-specific PDEs (PDE7), and high-affinity cGMP-specific PDEs (PDE9). E is They can also be divided into three broad groups based on the selectivity of their catalysts for cyclic nucleotides: cyclic AMP-specific PDEs (PDE4, PDE7, and PDE8), cyclic GMP-specific PDEs (PDE5, PDE6, and PDE9), and PDEs that lack the specificity to hydrolyze both cyclic nucleotides (PDE1, PDE2, PDE3, PDE10, and PDE11).

[0024] In an embodiment, the PDE inhibitor useful in the methods and compositions described herein is a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 or PDE11 inhibitor. A PDE4 inhibitor is a compound that prevents the decomposition action of phosphodiesterase 4 on cyclic adenosine monophosphate (cAMP). PDE4 acts as the major negative regulator of intracellular cyclic AMP in the central nervous system, and is a key activity of PDE4 in maintaining cyclic AMP signaling compartmentalization, which is involved in a wide range of neurological diseases and injuries.

[0025] Ibudilast is a small molecule drug (molecular weight 230.3) having the structure shown below.

[0026] [ka]

[0027] Ibudilast can also be found in ChemBank ID 3227, CAS number 50847-11-5 and Beilstein Handbook Reference No. 5-24-03-00396. Its molecular formula is C 14 H 18 It corresponds to NO. Ibudilast is also known by various chemical names, including 2-methyl-1-(2-(1-methylethyl)pyrazolo(1,5-a)pyridin-3-yl)1-propanone; 3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; and 1-(2-isopropyl-pyrazolo[1,5-a]pyridin-3-yl)-2-methyl-propan-1-one. Other synonyms of ibudilast include Ibudilastum (Latin), BRN0656579, KC-404, and MN-166. Its trade name is Ketas®. As referred to herein, ibudilast is intended to include any and all pharma- ceutically acceptable salt forms, prodrug forms (e.g., the corresponding ketals), solvates, etc., as appropriate for use in the formulations intended for its administration.

[0028] Ibudilast is a selective inhibitor of cyclic nucleotide phosphodiesterases (PDE) 3A, 4, 10A1, and 11A1 (Gibson et al., Eur J Pharmacol 538: 39-42, 2006), and has also been reported to have leukotriene D4 and PAF antagonist activity. Ibudilast acts to suppress inflammation through its effect on inflammatory cells (e.g., glial cells), thereby suppressing both the release of proinflammatory and neuroactive mediators. Ibudilast can also suppress the production of proinflammatory cytokines (IL-1β, TNF-α) and enhance the production of anti-inflammatory cytokines (IL-4, IL-10).Relevant references include: Obernolte, R. et al. (1993) "The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family" Gene 129: 239-247; Rile, G. et al. (2001) "Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells" Thromb. Res. 102: 239-246; Souness, J. E. et al. (1994) "Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone" Br. J. Pharmacol. 111: 1081-1088; Suzumura, A. et al. (1999) "Ibudilast suppresses TNF.alpha.production by glial cells functioning" Br. J. Pharmacol. 111: 1081-1088. "mainly as type III phosphodiesterase inhibitor in CNS" Brain Res. 837: 203~212; Takuma, K. et al. (2001) "Ibudilast attenuates astrocyte apoptosis via cyclic GMP signaling pathway in an in vitro reperfusion model" Br. J. Pharmacol. 133: 841~848.

[0029] Additional PDE inhibitors that can be utilized in the methods described herein include, but are not limited to, the following: PDE1 inhibitors vinpocetine, IC224, IC86340, IC295, diocrein, nicardipine, phenothiazines, calmidazolium, SCH51866, nimodipine and amantadine; PDE2 inhibitors luteolin, exisulind, oxindole, IC933, BAY60-7550 and EHNA; PDE3 inhibitors cilostazol, milrinone, cilostamide, pimobendan, IBMX, trequinsin, zardaverine, siguazodan, enoximone and PQ-10; PDE4 inhibitors Apremilast, Cilomilast, Crisaborole, Diazepam, Luteolin, Mesembrenone, Piclamilast, Roflumilast, Rolipram, Pentoxifylline, Etazolate, Trafentrin, Oglemilast, GSK256066, IBMX, Mesembrine, AWD12-281, SCH351591, V-11294A, HT0712, Denbufylline, RO 20-1724, BPN14770, IC486051, Etazolate, GEBR-7b, GSK356278, MK-0952 and L-454560; The PDE5 inhibitors mirodenafil, sildenafil, tadalafil, vardenafil and avanafil, sildenafil, sildenafil citrate, tadalafil, icariin, udenafil, DA-8159, SK&F96231, zaprinast and cilomilast; PDE7 inhibitors include quinazolines, BRL 50481, dipyridamole, thiadiazoles, ASB16165, S14 and VP1.15; PDE9 inhibitors SCH81566, zaprinast, BAY 73-6691 and PF-04447943; PDE10 inhibitors TAK-063, zaprinast, dipyridamole, papaverine, PQ-10, TP-10 and PF-02545920; and The PDE11 inhibitors tadalafil, BC11-38, zaprinast and dipyridamole.

[0030] Some of these PDE inhibitors, and a discussion of the use of PDE inhibitors in the treatment of neurodegenerative disorders, are described in Umar and Hoda, "Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders," Med. Chem. Commun. 6:2063-2080 (2015); and Knott et al., "Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair," International Journal of Molecular Sciences 18:696 (2017) (the disclosures of each of the PDE inhibitors are incorporated by reference herein in their entirety, particularly for disclosure of exemplary PDE inhibitors for use in the treatment of neurodegenerative disorders).

[0031] Nicotinamide riboside is a nicotinamide adenine dinucleotide (NAD + Nicotinamide riboside is a pyridine-nucleoside form of niacin (i.e., vitamin B3) that serves as a precursor to niacin. As used herein, "nicotinamide riboside" also includes nicotinamide riboside salts, such as nicotinamide riboside chloride. The chemical structure of nicotinamide riboside is shown below:

[0032] [ka]

[0033] Pterostilbene is a stilbenoid and an analogue of the polyphenol resveratrol with good bioavailability due to the presence of two methoxy groups that allow for improved lipophilicity and oral absorption, and a longer half-life due to reduced oxidation. The chemical structure of pterostilbene is shown below:

[0034] [ka]

[0035] As previously mentioned, reference to any one or more of the drugs described herein, particularly pterostilbene, nicotinamide riboside and ibudilast, is meant to encompass, where applicable, all enantiomers, mixtures of enantiomers, including racemic mixtures, prodrugs, pharma- ceutically acceptable salt forms, hydrates (e.g., monohydrate, dihydrate, etc.), solvates, and various physical forms.

[0036] In further embodiments, a thiol / cysteine ​​donor, such as acetylcysteine, may be added to the composition and / or administered to the subject to enhance treatment.

[0037] [Description of the Invention] Sirtuins, NAD+-dependent histone deacetylases, are emerging therapeutic targets for ALS. Sirtuins regulate cellular processes involved in ALS, specifically the maintenance of mitochondrial function. Importantly, alterations in sirtuin levels have been observed in ALS mouse models and tissues from ALS patients, resulting in adverse effects on mitochondrial biogenesis, function and turnover. Thus, measures to maintain sirtuin activity represent a promising therapeutic strategy for ALS. Elysium Health has developed EH301, which contains two active ingredients - nicotinamide riboside (250 mg) and pterostilbene (50 mg) - that increase NAD+ levels and support sirtuin activity. EH301 was effective in a placebo-controlled double-blind human pilot study in ALS patients. After 4 months of treatment, significant improvements were observed in the EH301 treatment group compared to placebo at 4 months in all ALS-specific endpoints, including: ALSFRS-R score: 2.5 point improvement in the EH301 group compared to a 5.5 point decline in the placebo group (difference between placebo and EH301 at 4 months = 6.1 points) FVC: 2.5% improvement in the EH301 group compared to a 16.6% decline in the placebo group (difference between placebo and EH301 at 4 months = 19.4%) MRC scale index: 17-point improvement in the EH301 group compared to an 11-point decline in the placebo group (difference between placebo and EH301 at 4 months = 23 points)

[0038] These results were accompanied by a significant improvement in muscle activity within the triceps as measured by electromyography. All participants in this study were also taking riluzole. No side effects attributable to the investigational drug were observed in any of the study participants at this dose.

[0039] As described herein with respect to the disclosed compositions and methods, the therapeutic benefit of EH301 is further enhanced by the addition of a phosphodiesterase (PDE) inhibitor, including PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 and PDE11 inhibitors, and in embodiments, a PDE4 inhibitor, such as ibudilast. Ibudilast is considered to be a relatively non-specific PDE, but ibudilast maximally inhibits the PDE4 subtype. Indeed, a significant improvement in survival was observed in SOD1-G93A mice treated with nicotinamide riboside and pterostilbene (EH301) and ibudilast from day 50 (mean survival time=191 days) compared to mice treated with either EH301 (mean survival time=153 days) or ibudilast (mean survival time=137 days) (P<0.01) (see FIG. 1 and Table 1). As illustrated in Figure 1, these findings demonstrate a synergistic interaction between EH301 and ibudilast, extending median survival by 38 days compared to EH301 alone and 54 days compared to ibudilast alone. These are surprising and unexpected results, and represent the unique advantages provided herein over prior therapies for the treatment of ALS.

[0040] The combination of EH301 - which contains two active ingredients, nicotinamide riboside and pterostilbene - with PDE inhibitors, including PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 and PDE11 inhibitors, and in exemplary embodiments, PDE4 inhibitors, represents an ALS-specific treatment strategy to provide improved survival, treatment and / or prevention of motor neuron diseases and disorders (e.g., ALS) and / or slow or reverse motor neuron degeneration.

[0041] Accordingly, provided herein are methods and compositions relating to treating and / or preventing motor neuron diseases and disorders (e.g., ALS) and / or slowing or reversing motor neuron degeneration by administering to a subject in need thereof (e.g., a subject having ALS) a composition comprising a compound of Formula I or Formula II (e.g., nicotinamide riboside), a compound of Formula III (e.g., pterostilbene), and a phosphodiesterase (PDE) inhibitor, such as a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 or PDE11 inhibitor, preferably, for example, ibudilast.

[0042] Thus, such combination therapy includes sequential, simultaneous and separate or co-administration of the above compounds of the present invention. In an embodiment, the therapeutic effect of the first compound administered is not completely lost when the subsequent compound is administered. That is, the therapeutic effect of the compounds of formula I and / or formula II (either alone or in combination) is not completely lost when the subsequent compound, including the PDE inhibitor, is administered.

[0043] As provided herein, pharmaceutical compositions comprising a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof may be provided having the following general chemical structure: [ka] wherein, independently for each occurrence: R1, R2 and R3 are hydrogen, halogen, -CN, -NO2, -OR 14 , -N(R 14 ) m , -R 13 , substituted or unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; R4 and R5 are hydrogen, halogen, -CN, -NO2, -OR 14 , -N(R 14 ) m , substituted or unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; R6, R8, R 11 and R 12 is hydrogen, (C1-C6) alkyl, -((C1-C6) alkylene)N(R 14 ) m , -C(O)((C1-C6) alkylene)N(R 14 ) m , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, -OR 14 and -N(R 14 ) m is selected from R7, R9 and R 10 is -((C1-C6) alkylene)N(R 14 ) m , -OR 14 and -N(R 14 ) m is selected from R 13 -OR 14 , -N(R 14 ) m , -C(O)(R 14 ), -C(O)(OR 14 ), -C(O)N(R 14 ) m , -S(O)2(OR 14 ), -S(O)OR 14 and -S(O)2N(R 14 ) m is selected from R14 is selected from hydrogen, (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; X is O, S or N(R 14 ) and m is 2 or 3; However, at least one of R1, R2, and R3 is R 13 is) The compounds include those having the formula:

[0044] In some embodiments, R is R 13 In some embodiments, R2 is R 13 In some embodiments, R3 is R 13 It is.

[0045] In some embodiments, R 13 -OR 14 , -N(R 14 ) m , -C(O)(R 14 ), -C(O)(OR 14 ) and -C(O)N(R 14 ) m In some embodiments, R 13 is -C(O)(R 14 ), -C(O)(OR 14 ) and -C(O)N(R 14 ) m In some embodiments, R 13 -C(O)N(R 14 ) m It is.

[0046] In some embodiments, R, R and R 10 are independently -OR 14 Or -N(R 14 ) m In some embodiments, R7, R9 and R 10 -OR 14 It is. In some embodiments, the compound of formula (I) has formula (II): [ka] wherein, independently for each occurrence: R2 and R3 are hydrogen, halogen, -CN, -NO2, -OR 14 , -N(R 14 ) m , -R 13 , substituted or unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; R4 and R5 are hydrogen, halogen, -CN, -NO2, -OR 14 , -N(R 14 ) m , substituted or unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; R6, R8, R 11 and R 12 is hydrogen, -OR 14 , -N(R 14 ) m , substituted or unsubstituted (C1-C6) alkyl, -((C1-C6) alkylene)N(R 14 ) m , -C(O)((C1-C6) alkylene)N(R 14 ) m , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; R 13 -OR 14 , -N(R 14 ) m , -C(O)(R 14 ), -C(O)(OR 14 ), -C(O)N(R 14 ) m , -S(O)2(OR 14 ), -S(O)OR 14 and -S(O)2N(R 14 ) m is selected from R 14is selected from hydrogen, (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; m is 2 or 3) or a pharma- ceutically acceptable salt thereof.

[0047] In some embodiments of the compounds of Formula (I) or (II), R1, R2, and R3, when present, are each independently selected from hydrogen, halogen, -CN, -NO2, -OR 14 , -N(R 14 ) m , -R 13 and substituted or unsubstituted (C1-C6) alkyl. In some embodiments, R1, R2, and R3 are each independently selected from hydrogen, -OR 14 , -N(R 14 ) m and unsubstituted (C1-C6) alkyl. In some embodiments, R1, R2, and R3, when present, are each independently selected from substituted or unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. In some embodiments, R1, R2, and R3, when present, are each independently selected from hydrogen.

[0048] In some embodiments of the compounds of Formula (I) or (II), R4 and R5 are each independently hydrogen, halogen, -CN, -NO2, -OR 14 , -N(R 14 ) m and substituted or unsubstituted (C1-C6) alkyl. In some embodiments, R4 and R5 are each independently selected from hydrogen, -OR 14 , -N(R 14 ) mand unsubstituted (C1-C6) alkyl. In some embodiments, R4 and R5 are each independently selected from substituted or unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. In some embodiments, R4 and R5 are each hydrogen.

[0049] In some embodiments of the compounds of formula (I) or (II), R, R, R 11 and R 12 is hydrogen, -OR 14 , -N(R 14 ) m , unsubstituted (C1-C6) alkyl, -((C1-C6) alkylene)N(R 14 ) m , -C(O)((C1-C6) alkylene)N(R 14 ) m In some embodiments, R, R, R are selected from cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. 11 and R 12 each independently represents hydrogen, -OR 14 , -N(R 14 ) m , unsubstituted (C1-C6) alkyl, -((C1-C6) alkylene)N(R 14 ) m and -C(O)((C1-C6) alkylene)N(R 14 ) m In some embodiments, R, R, R 11 and R 12 each independently represents hydrogen, -OR 14 and -N(R 14 ) m In some embodiments, R, R, R 11 and R 12 are each independently selected from unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. 11 and R12 are hydrogen.

[0050] In some embodiments, R, R and R 10 are each independently -OR 14 Or -N(R 14 ) m In some embodiments, R7, R9 and R 10 are -OR 14 In some embodiments, R7, R9 and R 10 are -OH.

[0051] In some embodiments of the compounds of Formula (I) or (II), R 14 is hydrogen or (C1-C6) alkyl.

[0052] In some embodiments of the compound of Formula (I) or (II), X is O or N(R 14 In some embodiments, X is O.

[0053] In some embodiments of the compound of Formula (I) or (II), the compound is [ka] It is.

[0054] In some embodiments, the compound of formula (III): [ka] wherein, independently for each occurrence: R 15 is halogen, -CN, -NO2, -OR 16 , -N(R 16 ) p , -S(O)2(OR 16 ), -S(O)OR 16, substituted or unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; R 16 is selected from hydrogen, (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; n is an integer from 0 to 5; p is 2 or 3; However, at least one n is 1 and at least one R 15 -OR 16 and However, the compound of formula (III) [ka] isn't it) Provided herein is a pharmaceutical composition comprising a compound represented by the formula: or a pharma- ceutically acceptable salt thereof.

[0055] In some embodiments of the compound of Formula (III), R 15 is halogen, -CN, -NO2, -OR 16 , -N(R 16 ) p and substituted or unsubstituted (C1-C6) alkyl. 15 -OR 16 , -N(R 16 ) p and unsubstituted (C1-C6) alkyl. In some embodiments, R 15 is selected from substituted or unsubstituted (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. 15 -OR 16 In some embodiments, R 15 -OR 16 and R 16 is hydrogen or (C1-C6) alkyl. In some embodiments, R 15 -OR16 and R 16 is (C1-C6) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. 15 -OR 16 and R 16 is (C1-C6) alkyl. In some embodiments, R 15 -OR 16 and R 16 is (C1-C6) alkyl, cycloalkyl or heterocycloalkyl.

[0056] In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1 or 2.

[0057] In some embodiments, p is 2. In some embodiments, p is 3.

[0058] It is therefore noted that the present invention refers to pharma- ceutically acceptable compositions comprising a therapeutically effective amount of a compound of formula I or formula II (e.g., nicotinamide riboside), a compound of formula III (e.g., pterostilbene) and a phosphodiesterase (PDE) inhibitor, including a PDE4 inhibitor, e.g., ibudilast, such as a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 or PDE11 inhibitor, formulated together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents. In another aspect, the present invention refers to a kit-of-parts comprising a pharma- ceutically acceptable composition comprising a therapeutically effective amount of a compound of formula I or formula II (e.g. nicotinamide riboside) and a compound of formula III (e.g. pterostilbene), formulated together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents, and a further pharma- ceutically acceptable composition comprising a therapeutically effective amount of a phosphodiesterase (PDE) inhibitor, such as a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 or PDE11 inhibitor, including a PDE4 inhibitor, such as ibudilast, together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents. In another aspect, the present invention refers to a kit-of-parts comprising a first pharma- ceutically acceptable composition comprising a therapeutically effective amount of a compound of formula I or formula II (e.g., nicotinamide riboside), together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents; a second pharma- ceutically acceptable composition comprising a therapeutically effective amount of a compound of formula III (e.g., pterostilbene), together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents; and a third pharma- ceutically acceptable composition comprising a therapeutically effective amount of a phosphodiesterase (PDE) inhibitor, such as a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 or PDE11 inhibitor, including a PDE4 inhibitor, such as ibudilast, together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents.

[0059] Therefore, it is noted that the agents described herein, preferably nicotinamide riboside, pterostilbene and PDE inhibitors, such as ibudilast, can be administered as is, or in admixture with pharmaceutically acceptable carriers, or can be administered in combination with other agents.Therefore, combination therapy includes sequential, simultaneous and separate or co-administration of the above compounds of the present invention.In an embodiment, the therapeutic effect of the first compound administered is not completely eliminated when the subsequent compound is administered.This includes the embodiment when nicotinamide riboside and pterostilbene are administered separately and together, and when PDE inhibitors are administered together or separately from nicotinamide riboside and pterostilbene.

[0060] As described in detail below, the pharmaceutical compositions described herein may be specially formulated for administration in solid or liquid form, including: (1) oral administration, e.g., liquids (aqueous or non-aqueous solutions, or aqueous or non-aqueous suspensions), tablets, e.g., buccal, sublingual and those targeted for systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, e.g., by subcutaneous, intramuscular, intravenous or epidural injection, e.g., as a sterile solution or suspension, or sustained release formulation; or (3) those adapted for sublingual administration.

[0061] In some embodiments, the composition(s) include additional agents. For example, the composition(s) may include nutritional agents, such as antioxidants. Examples of pharma- ceutically acceptable antioxidants include (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc., (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, etc., and (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.

[0062] In exemplary embodiments, the compositions described herein may further comprise a thiol / cysteine ​​donor. In embodiments, a further thiol / cysteine ​​donor, acetylcysteine, may be included. Acetylcysteine, also known as N-acetyl-L-cysteine ​​(NAC) or N-acetylcysteine, is the amino acid L-cysteine ​​(Cys) with an acetyl group attached to the amino group, and has the following structure: [ka] has.

[0063] The addition of an acetyl group increases the water solubility of Cys, which functions to accelerate the absorption and distribution of orally ingested Cys. The acetyl group also reduces the reactivity of thiols (-SH), making NAC less toxic and less susceptible to oxidation compared to Cys. NAC is safe at higher doses and is a better source of Cys than Cys itself. Oral supplementation with NAC has been found to boost intracellular glutathione (GSH) via an increase in intracellular Cys. NAC is rapidly absorbed after oral administration, reaching maximum plasma levels within 2-3 hours with a half-life of approximately 6 hours. NAC readily enters cells and is hydrolyzed to cysteine.

[0064] The compositions and methods described herein can also include various NAC derivatives and pharma- ceutically acceptable salts thereof, including, for example, NAC amide, NAC ethyl ester, etc. For example, the thiol / cysteine ​​donor can be N-acetylcysteine ​​(NACA), as disclosed, for example, in Patel et al., "N-acetylcysteineamide Preserves Mitochondrial Bioenergetics and Improves Functional Recovery Following Spinal Trauma," Exp. Neurol. 257:95-105 (2014), the disclosure of which is incorporated herein by reference in its entirety.

[0065] Additional suitable cysteine ​​derivatives that can be utilized in the compositions, formulations, and methods described herein are described in Miura et al., “Antioxidant activities of cysteine ​​derivatives against lipid oxidation in anhydrous media,” Bioscience, Biotechnology, and Biochemistry 78: 1452-1455 (2014), the disclosure of which is incorporated herein by reference, and have the following structure: [ka] Includes.

[0066] Further N-acetylcysteine ​​derivatives are disclosed in Liu et al., "Identification of novel N-acetylcysteine ​​derivatives for the treatment of hepatocellular injury," Med. Chem. Commun. 8:2238-2247 (2017), the disclosure of which is incorporated herein by reference in its entirety. Liu et al. disclose several NAC derivatives, which are outlined in the schematic of FIG.

[0067] In particular, compounds 6a, 6b and 7a can be utilized in the compositions and methods described herein. Compound 6a-(R)-2-acetamido-N-cyclohexyl-3-(methylthio)propenamide; Compound 6b-(R)-N-cyclohexyl-3-(methylthio)-2-propionamidopropanamide; and Compound 7a-(R)-2-acetamido-3-(methylthio)-N-phenylpropanamide. Methods for preparing these compounds are thoroughly outlined in Liu et al.

[0068] In still further embodiments, the thiol / cysteine ​​donor can be N-acetylcysteine ​​benzyl ester or N-acetylcysteine ​​ethyl ether, as disclosed, for example, in Uemura et al., "Protective Effects of Brain Infarction by N-Acetylcysteine ​​Derivatives," Stroke 49:1727-1733 (2018), the disclosure of which is incorporated by reference in its entirety. Synthesis of these NAC derivatives is disclosed in Uemura et al., whose structures are illustrated below: [ka]

[0069] The amount of thiol / cysteine ​​donor, preferably acetylcysteine ​​or a derivative thereof, that may be included in the compositions described herein can be determined by one of skill in the art and is generally in the range of about 25 mg to about 1000 mg, about 100 mg to about 1000 mg, about 25 mg to about 500 mg, about 25 mg to about 200 mg, about 25 mg to about 250 mg, about 30 mg to about 225 mg, about 40 mg to about 200 mg, about 45 mg to about 250 mg, or about 25 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, or about 150 mg.

[0070] Additional compounds that may be included in the compositions and formulations described herein include, for example, acamprosate, baclofen, cinacalcet, mexiletine, sulfisoxazole, torasemide, and riluzole.

[0071] The preparation of the compound described herein can be provided in unit dosage form and can be prepared by any method well known in the pharmaceutical field.The amount of active ingredient that can be combined with carrier material to produce single dosage form varies depending on the host treated and specific mode of administration.The amount of active ingredient that can be combined with carrier material to produce single dosage form is generally the amount of drug that produces therapeutic effect.

[0072] In certain embodiments, the formulations described herein comprise an excipient, including but not limited to cyclodextrins, liposomes, micelle-forming agents, such as bile acids, and polymeric carriers, such as polyesters and polyanhydrides, and an agent of the invention. In some embodiments, the formulations render the agent of the invention orally bioavailable. Methods of preparing these formulations or compositions can include bringing into association a compound of the invention with the carrier and, optionally, one or more accessory ingredients.

[0073] The liquid dosage form for oral administration of the formulations provided herein includes pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.The liquid dosage form may contain, in addition to the active ingredient, inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and sorbitan fatty acid esters, and mixtures thereof.

[0074] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0075] Suspensions may contain, in addition to the active compound, suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

[0076] Formulations provided herein suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (with flavored bases, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a pastille (with an inert base, such as gelatin and glycerin, or sucrose and acacia), and / or as a mouthwash, and the like, each containing a predetermined amount of a compound of the invention as an active ingredient. The compounds of the invention may also be administered as a bolus, electuary, or paste.

[0077] In solid dosage forms of the invention for oral administration (e.g., capsules, tablets, pills, dragees, powders, granules, etc.), the active ingredient may be incorporated into one or more pharma- ceutically acceptable carriers, e.g., sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, such as glycerol; (4) disintegrants, e.g., glycerol; For example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarders, such as paraffin; (6) absorption enhancers, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol, glycerol monostearate, and nonionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets, and pills, the pharmaceutical compositions may also contain buffering agents. Solid compositions of a similar type may also be used as fillers in soft and hard shell gelatin capsules using such excipients as lactose or milk sugar, and high molecular weight polyethylene glycols.

[0078] Tablets may be produced by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surfactants or dispersing agents. Molded tablets may be produced by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0079] Tablets and other solid dosage forms of the pharmaceutical compositions described herein, such as dragees, capsules, pills and granules, may be optionally scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They may also be formulated to provide delayed or controlled release of the active ingredient herein, for example using hydroxypropylmethylcellulose in various proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. The compositions described herein may also be formulated for immediate release, such as lyophilization. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid composition that may be dissolved in sterile water or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents, and may be compositions that release the active ingredient(s) only, or preferentially in a certain part of the gastrointestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0080] Pharmaceutical composition(s) provided herein suitable for parenteral administration contain one or more compounds of the invention in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders that can be reconstituted immediately before use into sterile injectable solutions or dispersions, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.

[0081] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, and the like) and suitable mixtures thereof, coconut oil, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0082] (Treatment method) Provided herein is a method for treating a motor neuron disease or disorder in a subject by administering to the subject (e.g., a subject in need thereof) a therapeutically effective amount of a compound of formula I or formula II (e.g., nicotinamide riboside), a compound of formula III (e.g., pterostilbene) and a phosphodiesterase (PDE) inhibitor, such as a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 or PDE11 inhibitor, including a PDE4 inhibitor, such as ibudilast. In further embodiments, a further compound, including a thiol / cysteine ​​donor, such as acetylcysteine, may also be administered together with NR, PT and a PDE4 inhibitor. Thus, such administration should refer to combination therapy, including sequential, simultaneous and separate or co-administration of the above compounds of the present invention. In an embodiment, the therapeutic effect of the first compound administered is not completely eliminated when the subsequent compound is administered.

[0083] In some aspects, provided herein is a method for slowing or reversing the progression of motor neuron degeneration in a subject, comprising administering to the subject (e.g., a subject in need thereof) a therapeutically effective amount of a compound of Formula I or Formula II (e.g., nicotinamide riboside), a compound of Formula III (e.g., pterostilbene), and a phosphodiesterase (PDE) inhibitor, such as a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10, or PDE11 inhibitor, including a PDE4 inhibitor, such as ibudilast. In some embodiments, motor neuron degeneration refers to neuronal death and / or loss of neuronal function.

[0084] In some embodiments, the subject may have or be susceptible to a motor neuron disease (e.g., amyotrophic lateral sclerosis (ALS), e.g., medullary ALS or brainstem ALS). A motor neuron disease or disorder may be any disease or disorder that affects the function or structure of motor neurons. As used herein, a motor neuron disease includes progressive diseases that result in loss of function of motor neurons or nerves in the brain and spinal cord. Examples of motor neuron diseases include amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia (HSP), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP), pseudobulbar palsy or spinal muscular atrophy. A motor neuron disease may affect upper or lower motor neurons.

[0085] The actual dosage levels and dosing regimens of the compositions disclosed herein may be varied to obtain an amount of a compound of Formula I or Formula II (e.g., nicotinamide riboside), a compound of Formula III (e.g., pterostilbene), and a phosphodiesterase (PDE) inhibitor, such as a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10, or PDE11 inhibitor, including a PDE4 inhibitor, such as ibudilast, that is not toxic to the patient and is effective to achieve the desired therapeutic response for the particular patient, composition, and mode of administration. The dosage of a thiol / cysteine ​​donor, such as acetylcysteine, that may be administered is also not toxic to the patient and is effective to achieve the desired therapeutic response for the particular patient, composition, and mode of administration, and generally ranges from about 50 to 200 mg / kg, preferably about 80 to 150 mg / kg, or about 100 mg / kg.

[0086] In some embodiments, administering the composition comprises administering the composition in one or more dose(s). In some embodiments, administering the composition comprises administering the composition in one or more, 5 or more, 10 or more, 20 or more, 30 or more, 40 or more, 50 or more, 100 or more, or 1000 or more dose(s). In some embodiments, the dose comprises at least 100 mg, at least 200 mg, at least 300 mg, at least 400 mg, at least 500 mg, at least 600 mg, at least 700 mg, at least 800 mg, at least 900 mg, at least 1000 mg, at least 1100 mg, at least 1200 mg, at least 1300 mg, at least 1400 mg, at least 1500 mg, at least 1600 mg, at least 1700 mg, at least 1800 mg, at least 1900 mg, at least 2000 mg, at least 2100 mg, at least 2200 mg, at least 2300 mg, at least 2400 mg, at least 2500 mg, at least 2600 mg, at least 2700 mg, at least 2800 mg, at least 2900 mg, or at least 3000 mg of a compound of Formula I or Formula II (e.g., nicotinamide riboside). In some embodiments, the dose comprises at least 5 mg, at least 10 mg, at least 20 mg, at least 30 mg, at least 40 mg, at least 50 mg, at least 60 mg, at least 80 mg, at least 100 mg, at least 120 mg, at least 140 mg, at least 160 mg, at least 180 mg, at least 200 mg, at least 220 mg, at least 240 mg, at least 260 mg, at least 280 mg, at least 300 mg, at least 320 mg, at least 340 mg, at least 360 mg, at least 380 mg, at least 400 mg, at least 500 mg, at least 600 mg, at least 700 mg, at least 800 mg, at least 900 mg, or at least 1000 mg of a compound of formula III (e.g., pterostilbene).

[0087] In exemplary embodiments, nicotinamide riboside or an equivalent thereof, alone or in combination with pterostilbene or an equivalent thereof, is administered to a patient (either via a single composition or in multiple separate compositions) in an amount of about 50 mg to about 1500 mg, about 100 mg to about 1500 mg, about 100 mg to about 1000 mg, about 125 mg to about 900 mg, about 150 mg to about 850 mg, about 200 mg to about 700 mg, about 200 mg to about 500 mg, about 1000 mg to about 1500 mg, or about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, or about 700 mg. Preferably, these amounts are administered to the patient daily in the form of a single composition or multiple compositions.

[0088] In an exemplary embodiment, pterostilbene or its equivalent, alone or in combination with nicotinamide riboside or its equivalent, is administered to a patient in an amount of about 25 mg to about 1000 mg, about 100 mg to about 1000 mg, about 25 mg to about 500 mg, about 25 mg to about 200 mg, about 25 mg to about 250 mg, about 30 mg to about 225 mg, about 40 mg to about 200 mg, about 45 mg to about 250 mg, or about 25 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, or about 150 mg per day (either via a single composition or in multiple separate compositions). Suitably, these amounts are administered to a patient daily in the form of a single composition or multiple compositions.

[0089] In some embodiments, the dose is in the range of about 30 mg to 240 mg, about 30 mg to 180 mg, 60 mg to 120 mg, or 20 mg to 80 mg of a PDE4 inhibitor, such as a phosphodiesterase (PDE) inhibitor, including ibudilast, such as a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10, or PDE11 inhibitor. For example, a PDE inhibitor, including a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10, or PDE11 inhibitor, such as those described herein, may be administered in the range of about 10 mg to 500 mg, about 20 mg to about 400 mg, about 30 mg to about 300 mg, about 40 mg to about 200 mg, about 50 mg to about 100 mg, about 20 mg to about 200 mg, including values ​​and ranges within these ranges. The compound may be administered in an amount of about 0 mg, about 20 mg to about 100 mg, about 20 mg to about 50 mg, or about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, or about 200 mg.

[0090] In some embodiments, the dosage comprises an amount of a thiol / cysteine ​​donor, such as acetylcysteine, in the range of about 30 mg to 240 mg, about 30 mg to 180 mg, 60 mg to 120 mg, or 20 mg to 80 mg.

[0091] The compositions disclosed herein may be administered for any period that is not toxic to the patient and is effective for achieving the desired therapeutic response for the particular patient, composition, and mode of administration. The period may be at least 1 day, at least 10 days, at least 20 days, at least 30 days, at least 60 days, at least 3 months, at least 6 months, at least 1 year, at least 3 years, at least 5 years, or at least 10 years. Doses may be administered sporadically or at regular intervals as needed. For example, doses may be administered monthly, weekly, every 2 weeks, every 3 weeks, once a day, or twice a day.

[0092] In some embodiments, the subject is administered a test to measure the general or symptomatic progression of the motor neuron disease. In some embodiments, the subject is administered a motor function test and / or a cognitive and behavioral function test. The motor function test can be the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). The cognitive and behavioral test can be the Complutense Verbal Learning Test (TAVEC), the Symbol Digit Modality Test (SDMT), the Verbal Fluency Test, the Digit Spanning Test (Wechsler Memory Test III), the D2 Attention Test, the Wechsler Memory Test III for Letters and Numbers, the Tower of London Test, the Stroop Test, the Behavioral Scale for Frontal Lobe Function (FrSBe) and / or a Brief Test (subjective behavior). In some embodiments, the subject is administered both a motor function test and a cognitive function test. The motor function test or the cognitive function test can be administered to the subject once or multiple times.

[0093] In some embodiments, the method further includes measuring a characteristic in the subject, such as a characteristic associated with inflammation. In some embodiments, the characteristic is measured by a blood test. Examples of characteristics that may be tested include levels of cytokines, levels of amyloid A protein, levels of macrophage activation marker neopterin, levels of creatine phosphokinase (CPK), levels of erythrocyte sedimentation rate, levels of C-reactive protein, plasma viscosity, and / or white blood cell count. In some embodiments, the cytokine is a pro-inflammatory cytokine. In some embodiments, the cytokine is an anti-inflammatory cytokine. Examples of cytokines include, but are not limited to, TNFα, IFNγ, IL-1, IL-6, IL-8, or TGFβ.

[0094] In some embodiments, the method further comprises administering a fatty acid supplement to the subject. In some embodiments, the fatty acid supplement comprises an oil. The oil may be processed (e.g., refined, bleached, or deodorized). In other embodiments, the oil is unprocessed or virgin oil. In some embodiments, the fatty acid supplement is derived or fractionated from a source to obtain isolated fatty acids. In some embodiments, the oil is coconut oil. Coconut oil, as used herein, may include any oil produced from the coconut kernel. The fatty acids found in the supplements disclosed herein may be short-chain fatty acids, medium-chain fatty acids, or long-chain fatty acids. Exemplary fatty acids that may be found in the supplements include, but are not limited to, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, and / or linolenic acid. The fatty acid supplements disclosed herein may comprise saturated fatty acids, unsaturated fatty acids, monounsaturated fatty acids, and / or polyunsaturated fatty acids. In some embodiments, fatty acid supplements can include hydrogenated oil. Fatty acid supplements can include one or more fatty acids. The actual dosage levels and administration regimens of the fatty acid supplements disclosed herein can be varied to obtain an amount of fatty acid supplement that is not toxic to patients and is effective to achieve the desired therapeutic response for a particular patient, composition and mode of administration.

[0095] As described herein, in further embodiments, the composition and method further comprises administration of a thiol / cysteine ​​donor, such as acetylcysteine.As shown in the examples, surprisingly, the addition of a thiol / cysteine ​​donor, such as acetylcysteine, alone or in combination, leads to a greater improvement in the general or symptomatic progression of the treatment of motor neuron disease than that experienced by any of the individual compounds (i.e., nicotinamide riboside, pterostilbene), phosphodiesterase (PDE) inhibitors and / or acetylcysteine.This synergistic finding is a surprising and unexpected advantage of the composition and method described herein.

[0096] The following examples are for illustrative purposes only and are not intended to limit the invention. EXAMPLES

[0097] [Glossary] Pterostilbene (PT), nicotinamide riboside (NR), EH301 [nicotinamide riboside (NR) and pterostilbene (PT)], dexamethasone (DXM) and ibudilast (IB).

[0098] [the purpose] The purpose of these examples is to investigate whether potential anti-neuroinflammatory drugs, such as dexamethasone or ibudilast, can further improve or enhance the effects of nicotinamide riboside (NR) and pterostilbene (PT) on motor function in a mouse model of ALS.

[0099] [Materials / Methods and Results] mouse 1.B6.Cg-Tg(SOD1 * G93A)1Gur / J(https: / / www.jax.org / strain / 004435) Mice hemizygous for the SOD1-G93A (also referred to as G93A-SOD1) transgene are viable, fertile, and have transgenic expression of the G93A mutant form of human SOD1. This founder line (often referred to as G1H) has been reported to have a high transgene copy number. Hemizygotes display a phenotype similar to amyotrophic lateral sclerosis (ALS) in humans, resulting in paralysis due to loss of motor neurons from the spinal cord, resulting in the paralysis of one or more limbs. Motor neuron degeneration has been associated with the function and / or degeneration of astrocytes, the major glial cell type of the nervous system. Transgenic mice have a short life span: 50% survive 157.1 + / - 9.3 days (compared to a mixed B6SJL background where 50% survival is observed at 128.9 + / - 9.1 days). Female hemizygotes have low fertility and rarely produce more than one litter before the onset of disease. Compared with LPS-induced microglia and activated M1 / M2 macrophages, spinal microglia activated by disease progression do not upregulate genes that indicate a bias toward either the M1 (neurotoxic) or M2 (protective) phenotype. The pattern of gene expression in SOD1G93A-activated microglia represents a unique ALS-specific signature. Thus, these SOD1-G93A (also called G93A-SOD1) transgenic mice are useful for studying neuromuscular disorders, including amyotrophic lateral sclerosis.

[0100] The SOD1-G93A transgene was designed with a mutant human SOD1 gene (harboring a single amino acid substitution of glycine to alanine at codon 93) driven by its endogenous human SOD1 promoter. This transgene was injected into fertilized B6SJLF1 mouse eggs to obtain founder animals. Transgenic mice in a mixed B6SJL genetic background were sent to Jackson Laboratory (as accession no. 002726). Upon arrival, several mice were backcrossed to C57BL / 6J for at least 10 generations to produce this congenic strain (accession no. 004435). Backcrossing was completed in July 2002.

[0101] 2.FUS-R521C mice FUS-R521C mice (ALS model; transgene injected into B6SJL oocytes and maintained in C57BL / 6 so that subsequent generations have a higher percentage of C57BL / 6) were selected for the method to examine the effect of adding acetylcysteine.

[0102] [Control / Non-carrier] B6SJLF1 / J (https: / / www.jax.org / strain / 100012). Produced by mating C57BL / 6J (B6) female mice with SJL / J (SJL) male mice. B6SJLF1 / J mice are heterozygous for the B6 and SJL alleles at all loci in their genome. This strain is often used for the production of transgenic mice.

[0103] [treatment] EH301 [nicotinamide riboside (NR) and pterostilbene (PT)] was administered orally: 185 mg nicotinamide riboside and 30 mg pterostilbene / Kg×day (Estrela JM, De La Rubia JE, Dellinger RW. Treating and preventing motor neuron disease using nicotinamide riboside. International Application PCT / US 18 / 32932, 2018).

[0104] Dexamethasone (DXM) was administered intraperitoneally in the following sequential 4-week cycles in parallel with the experimental time: 1 mg / Kg x day (week 1), 0.5 mg / Kg x day (week 2), 0.25 mg / Kg x day (week 3), 0.0 mg / Kg x day (week 4). The dose of 1 mg / Kg was chosen based on Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybylkowski A, Czlonkowski A, Czlonkowska A. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int Immunopharmacol. 2004 Oct;4(10-11):1307-18. The cycle dose regimen was designed to optimize therapeutic benefit and minimize possible side effects.

[0105] Ibudilast (IB) was administered orally: 12 mg / kg × day (Wang H, Mei Zl, Zhong KL, Hu M, Long Y, Miao MX, Li N, Yan TH, Hong H. Pretreatment with antiasthmatic drug ibudilast ameliorates Aβ 1-42-induced memory impairment and neurotoxicity in mice. Pharmacol Biochem Behav. 2014 September;124:373-9).

[0106] Acetylcysteine ​​(NAC) was administered intraperitoneally (IP): 100 mg / kg per day, starting at week 30 in experiments investigating the additive effect of NAC.

[0107] Daily doses of NR, DXM and IB were administered together in 75 μL of saline. PT was included in the experimental animals' chow. PT doses were adjusted based on the animals' body weight and daily food intake.

[0108] [Table 1]

[0109] [Table 2]

[0110] This neurological score is based on the scale of Weydt et al. (Weydt, P., Hong, SY, Kliot, M., Moller, T. 2003. Assessing disease onset and progression in the SOD1 mouse model of ALS. NeuroReport 14, 1051-1054). A score from "0" to "5" is defined as follows: "0" indicates a healthy mouse without typical signs of ALS; "1" indicates the presence of tremors in the hind limbs, which occurs early in the disease; "2" indicates that when the mouse is suspended by its tail, it has difficulty releasing its hind limbs, indicating muscle weakness; "3" is given if the mouse shows difficulty in walking, either stumbling or staggering; "4" is given if the mouse is unable to walk on all four limbs and drags its hind limbs; "5" is given if the mouse is unable to stand up again after 30 seconds. When animals reach a score of "4", food pellets are placed on the cage floor for all transgenic mice to promote access to food and water. When a score of "5" is reached, animals are euthanized for ethical reasons. Onset is defined as the shortest period during which mice show symptoms (score <4). Changes over time in the different groups were monitored weekly. The number of animals tested per week was identical to the number shown in Table 1 for each group.

[0111] [Table 3]

[0112] The function of the test includes evaluating the balance, grip strength and motor coordination of the subject, especially in testing the effect of experimental drugs. For this test (Rotarod, Harvard Apparatus, Holliston, MA), three trials were performed for each animal, and the maximum period (seconds) during which the animal could stay on the rotating shaft (diameter 3.5 cm, rotation speed: 15 rpm) without falling was measured. Each mouse was given a maximum of three attempts against an arbitrary limit of 1200 seconds, and the longest period was recorded. Changes over time in the different groups were monitored weekly. The number of animals tested per week was the same as that shown in Table 1 for each group.

[0113] The survival time of FUS-R521C mice treated with nicotinamide riboside (NR), pterostilbene (PT), ibudilast (IBU) and N-acetylcysteine ​​(NAC) is illustrated in Figures 3A-3C. As shown in Figure 3A, treatment with a combination of NR and PT extends survival time to about 35 weeks, while either drug alone extends survival time to about 28-32 weeks. In Figure 3B, the combination of NR, PT and ibudilast extends survival time to about 45 weeks, while ibudilast alone shows a survival time of about 30 weeks. In Figure 3C, the combination of NR, PT, ibudilast and N-acetylcysteine ​​(NAC) shows a survival time of more than 45 weeks (end of study), with about 2 / 3 of the mice surviving the entire study period. The combination of NR, PT and NAC shows a survival time of about 39-40 days, while NAC alone shows a survival time of about 32 days. These are surprising and unexpected results, showing that the combination of NR, PT, IBU and NAC dramatically extends survival in a mouse model, significantly outperforming any other combination and any other single compound.

[0114] (statistics) Data are expressed as the mean ± SD of a number of different experiments. Statistical analysis was performed using the Student's t test. * P<0.05 and ** P<0.01 comparing total SOD1 group vs. WT (wild type). + P<0.05 and++ *P<0.01 comparing all SOD1 groups treated with EH301, DXM, IB or their combinations vs. SOD1 untreated controls. a P<0.05 and aa P<0.01 comparing SOD1+EH301+DXM or SOD1+EH301+IB groups vs. SOD1+EH301. b P<0.05 and bb P<0.01 comparing SOD1+EH301+DXM or SOD1+EH301+IB groups vs. SOD1+DXM. c P<0.05 and cc P<0.01 comparing SOD1+EH301+DXM or SOD1+EH301+IB groups vs. SOD1+IB.

[0115] [Conclusion] The results presented herein confirm the findings presented in International Application PCT / US18 / 32932 and show that EH301 significantly extends survival time and improves motor neuron-dependent function in SOD1 mice, whereas administration of DXM or IB shows a modest improvement in both survival time and motor coordination compared to control untreated SOD1-G93A mice. Treatment with EH301 produces better results than DXM or IB.

[0116] The results with the combination of EH301 and DXM were not significantly different than EH301 alone, but notably, and as shown in this example, the results with the combination of EH301 and IB were significantly better than EH301 alone.

[0117] As shown in FIG. 1, a significant improvement in survival was observed in SOD1-G93A mice treated with EH301 and then ibudilast (mean survival time=191 days) from day 50 compared to mice treated with either EH301 (mean survival time=153 days) or ibudilast (mean survival time=137 days) (P<0.01).

[0118] It should be emphasized that the results presented here clearly suggest a synergistic effect of EH301 and IB that is far superior to any other options currently administered to patients or experimentally tested. Considering the special characteristics of ALS (no cure, no effective treatment, and even no way to halt or significantly slow its fatal progression), the cooperation of EH301 and IB may represent a promising new effective therapeutic approach for the treatment of this disease.

[0119] [Treatment with PDE inhibitors] EH301 [nicotinamide riboside (NR) and pterostilbene (PT)] is administered orally: 185 mg nicotinamide riboside and 30 mg pterostilbene / Kg x day.

[0120] PDE inhibitors (including PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10, or PDE11 inhibitors) are administered orally or intraperitoneally (depending on the type of compound) in amounts ranging from about 1 mg to 50 mg / Kg x day.

[0121] The daily doses of NR and PDE inhibitor are administered together in saline. PT is included in the experimental animals' chow. The PT dose is adjusted based on the animal's body weight and daily food intake.

[0122] Other experiments are designed to examine administration of NR and PT in a single composition, along with separate administration of a PDE inhibitor. In further experiments, NR, PT and a PDE inhibitor can be included in the same composition and administered together at the same time.

[0123] In embodiments in which NR and PT are administered in a single composition, the patient is administered a composition comprising a combination of 200 mg to about 700 mg of nicotinamide riboside and about 25 mg to about 200 mg of pterostilbene, including compositions comprising about 500 mg of nicotinamide riboside and about 100 mg of pterostilbene.

[0124] In other embodiments, a composition comprising a combination of about 250 mg nicotinamide riboside and about 50 mg pterostilbene is administered to the patient, hi further embodiments, two or more doses of such a composition may be administered such that a total of about 500 mg nicotinamide riboside and about 100 mg pterostilbene is administered to the patient daily.

[0125] PDE inhibitors, including PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10, or PDE11 inhibitors, are administered orally or intraperitoneally (depending on the type of compound) in amounts ranging from about 1 mg to 50 mg / Kg x day.

[0126] The levels of proinflammatory cytokines in the cerebrospinal fluid of healthy volunteers and ALS patients were determined as a result of treatment with EH301 alone and in combination with ibudilast. At the start of the procedure, the mean age of the healthy volunteers and ALS patients was 51.7 ± 3.6 years and 55.4 ± 4.8 years, respectively. The gender distribution (male / female) of the healthy volunteers and ALS patients was 8 / 4 (healthy volunteers), 6 / 4 (control ALS patients treated with placebo), 5 / 2 (ALS patients treated with EH301), 4 / 3 (ALS patients treated with EH301 and ibudilast). The ALS patients were randomly distributed among the different groups. All ALS patients had lumbar onset. At the start of the procedure, the duration of symptoms in the ALS patients ranged from 15 to 24 months. The ALSFRS-R (Revised ALS Functional Rating Scale) score was 30-40 in all cases at the start of the procedure. CSF samples were taken before treatment began (month 0) and at month 6.

[0127] The data presented below in Table 4 are the mean ± SD of the number of volunteers or patients. Data were analyzed by two-way analysis of variance (ANOVA) (SPSS 9.0 software for Windows; SPSS Inc., Chicago, IL). Homogeneity of variance was analyzed by Levene's test. The null hypothesis was accepted for all values ​​of tests that were not significant with F values ​​of P>0.05. Data with significant F values ​​were examined by Tukey's test with P<0.05. Different letters within a row indicate differences P<0.05 (a>b>c).

[0128] [Table 4]

[0129] This data indicates that the combination of EH301 and ibudilast is effective against neuroinflammation.

[0130] Although particular embodiments have been illustrated and described herein, it is to be understood that the claims should not be limited to the specific forms or arrangements of parts described and shown. Although exemplary embodiments have been disclosed and specific terms have been employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation. Modifications and variations of the embodiments are possible in light of the above teachings. It is therefore to be understood that the embodiments may be practiced otherwise than as specifically described.

[0131] Although various embodiments have been described above, it should be understood that they are presented only as illustrations and examples of the present technology, and not as a means of limitation. It will be apparent to those skilled in the art that various changes in form and detail can be made without departing from the spirit and scope of the present technology. Thus, the breadth and scope of the present technology should not be limited by any of the above-described embodiments, but should be defined only according to the appended claims and their equivalents. It will also be understood that each feature of each embodiment discussed in this specification and each reference cited in this specification can be used in combination with the features of any other embodiment. All patents and publications discussed in this specification are incorporated herein by reference in their entirety. Further embodiments are as follows. [Embodiment 1] A compound of formula I or formula II in combination with a compound of formula III and a phosphodiesterase (PDE) inhibitor for use in a method of treating or preventing amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising administering therapeutically effective amounts of a compound of formula I or formula II, a compound of formula III and a phosphodiesterase (PDE) inhibitor sequentially, simultaneously or separately, or as a co-administration to the subject. [Embodiment 2] The compound for use according to embodiment 1, wherein the therapeutic effect of the first compound administered is not completely abolished when the subsequent compound is administered. [Embodiment 3] The compound for use according to embodiment 1 or 2, wherein the compound of formula I or formula II is nicotinamide riboside. [Embodiment 4] The compound for use according to any one of embodiments 1 to 3, wherein the compound of formula III is pterostilbene. [Embodiment 5] The compound for use according to any one of embodiments 1 to 4, wherein the PDE inhibitor is a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 or PDE11 inhibitor. [Embodiment 6] The compound for use according to any one of embodiments 1 to 5, wherein the phosphodiesterase (PDE) inhibitor is a PDE4 inhibitor. [Embodiment 7] The compound for use according to any one of embodiments 1 to 6, wherein the phosphodiesterase (PDE) inhibitor is ibudilast. [Embodiment 8] The compound for use according to embodiment 7, wherein the phosphodiesterase (PDE) inhibitor is ibudilast, the compound of formula III is pterostilbene, and the compound of formula I is nicotinamide riboside. [Embodiment 9] The compound for use according to any one of embodiments 1 to 8, wherein the method further comprises the step of administering a fatty acid supplement to the subject. [Embodiment 10] The compound for use according to any one of embodiments 1 to 9, wherein the compound is included in a pharma- ceutically acceptable composition comprising a therapeutically effective amount of a compound of formula I or formula II, a compound of formula III and a phosphodiesterase (PDE) inhibitor, formulated together with one or more pharma- ceutically acceptable carriers (excipients) and / or diluents. [Embodiment 11] The compound for use according to any one of embodiments 1 to 9, wherein the compound of formula I or formula II and the compound of formula III are formulated together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents, and the phosphodiesterase (PDE) inhibitor is formulated separately with one or more pharma- ceutically acceptable carriers (additives) and / or diluents. [Embodiment 12] The compound for use according to any one of embodiments 1 to 9, wherein the compound of formula I or formula II, the compound of formula III and the phosphodiesterase (PDE) inhibitor are each formulated separately with one or more pharma- ceutically acceptable carriers (additives) and / or diluents. [Embodiment 13] A pharma- ceutically acceptable composition comprising a therapeutically effective amount of a compound of Formula I or Formula II, a compound of Formula III, and a phosphodiesterase (PDE) inhibitor, formulated together with one or more pharma- ceutically acceptable carriers (excipients) and / or diluents. [Embodiment 14] A kit of parts comprising a pharma- ceutically acceptable composition comprising a therapeutically effective amount of a compound of Formula I or Formula II and a compound of Formula III, formulated together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents, and a further pharma- ceutically acceptable composition comprising a therapeutically effective amount of a phosphodiesterase (PDE) inhibitor together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents. [Embodiment 15] A kit of parts comprising: a first pharma- ceutically acceptable composition comprising a therapeutically effective amount of a compound of formula I or formula II together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents; a second pharma-ceutically acceptable composition comprising a therapeutically effective amount of a compound of formula III together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents; and a third pharma-ceutically acceptable composition comprising a therapeutically effective amount of a phosphodiesterase (PDE) inhibitor together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents. [Embodiment 16] The pharma- ceutically acceptable composition of embodiment 13, wherein the phosphodiesterase (PDE) inhibitor is a PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, PDE10 or PDE11 inhibitor, the compound of formula III is pterostilbene, and the compound of formula I or formula II is nicotinamide riboside. [Embodiment 17] The pharma- ceutically acceptable composition of embodiment 16, wherein the phosphodiesterase (PDE) inhibitor is PDE4, the compound of formula III is pterostilbene, and the compound of formula I or formula II is nicotinamide riboside. [Embodiment 18] The pharma- ceutically acceptable composition of embodiment 17, wherein the PDE4 inhibitor is ibudilast. [Embodiment 19] 19. A pharma- ceutically acceptable composition according to any one of embodiments 16-18, wherein pterostilbene is present at about 250 mg and nicotinamide riboside is present at about 50 mg. [Embodiment 20] The compound for use according to any one of embodiments 1 to 12, wherein the compound is administered orally. [Embodiment 21] The compound for use according to any one of embodiments 1 to 12, further comprising a thiol / cysteine ​​donor. [Embodiment 22] The compound for use according to embodiment 21, wherein the thiol / cysteine ​​donor is selected from the group consisting of acetylcysteine, N-acetylcysteine ​​amide, (R)-2-acetamido-N-cyclohexyl-3-(methylthio)propenamide, (R)-N-cyclohexyl-3-(methylthio)-2-propionamidopropanamide, compound 7a-(R)-2-acetamido-3-(methylthio)-N-phenylpropanamide, N-acetylcysteine ​​benzyl ester and N-acetylcysteine ​​ethyl ether. [Embodiment 23] The compound for use according to embodiment 22, wherein the thiol / cysteine ​​donor is acetylcysteine. [Embodiment 24] The pharma- ceutically acceptable composition of embodiment 13, further comprising a thiol / cysteine ​​donor. [Embodiment 25] 25. The pharma- ceutically acceptable composition of embodiment 24, wherein the thiol / cysteine ​​donor is selected from the group consisting of acetylcysteine, N-acetylcysteine ​​amide, (R)-2-acetamido-N-cyclohexyl-3-(methylthio)propenamide, (R)-N-cyclohexyl-3-(methylthio)-2-propionamidopropanamide, compound 7a-(R)-2-acetamido-3-(methylthio)-N-phenylpropanamide, N-acetylcysteine ​​benzyl ester, and N-acetylcysteine ​​ethyl ether. [Embodiment 26] 26. The pharma- ceutically acceptable composition of embodiment 25, wherein the thiol / cysteine ​​donor is acetylcysteine.

Claims

1. A pharmaceutically acceptable composition for treating or preventing amyotrophic lateral sclerosis (ALS), comprising: comprising therapeutically effective amounts of nicotinamide riboside, pterostilbene, and a phosphodiesterase (PDE) inhibitor formulated together with one or more pharmaceutically acceptable carriers and / or diluents; A composition wherein the PDE inhibitor is ibudilast.

2. 2. The composition of claim 1, wherein pterostilbene is present at 250 mg and nicotinamide riboside is present at 50 mg.

3. The composition of claim 1 or 2, further comprising a thiol / cysteine ​​donor.

4. 4. The composition of claim 3, wherein the thiol / cysteine ​​donor is selected from the group consisting of acetylcysteine, N-acetylcysteine ​​amide, (R)-2-acetamido-N-cyclohexyl-3-(methylthio)propenamide, (R)-N-cyclohexyl-3-(methylthio)-2-propionamidopropanamide, (R)-2-acetamido-3-(methylthio)-N-phenylpropanamide, N-acetylcysteine ​​benzyl ester, and N-acetylcysteine ​​ethyl ether.

5. The composition of claim 4 , wherein the thiol / cysteine ​​donor is acetylcysteine.

Citation Information

Patent Citations

  • Treating and preventing motor neuron diseases using nicotinamide riboside

    WO2018213420A1